Finance

Beta
Lists
NOTA:FRA
Novartis AG
€131,00
-1,50%
(-2,00) 1D
15 ກ.ລ., 8 ໂມງ 2 ນາທີ 45 ວິນາທີ GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOTA...
Open
€131,00
High
€131,00
Low
€131,00
Mkt. cap
໒໔໙,໖໔ ຕື້
Avg. vol.
໑໓,໐໐
Volume
໐,໐໐
52-wk high
€145,00
52-wk low
€95,20
No. of employees
໗໕ ພັນ
Open
€131,00
High
€131,00
Low
€131,00
Mkt. cap
໒໔໙,໖໔ ຕື້
Avg. vol.
໑໓,໐໐
Volume
໐,໐໐
52-wk high
€145,00
52-wk low
€95,20
No. of employees
໗໕ ພັນ
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75,3 ພັນ
Founded29 ກ.ພ. 1996
Headquartersບາເຊວ, Basel City, ສະວິດເຊີແລນ
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ມິ.ຖ. 2025
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
Revenue
14,84 ຕື້
14,36 ຕື້
13,86 ຕື້
13,52 ຕື້
Cost of goods sold
3,32 ຕື້
3,54 ຕື້
3,54 ຕື້
3,44 ຕື້
Cost of revenue
3,32 ຕື້
3,54 ຕື້
3,54 ຕື້
3,44 ຕື້
Research and development expenses
2,62 ຕື້
2,86 ຕື້
2,84 ຕື້
2,78 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,44 ຕື້
3,30 ຕື້
3,44 ຕື້
3,14 ຕື້
Operating expense
6,05 ຕື້
6,24 ຕື້
6,46 ຕື້
5,96 ຕື້
Total operating expenses
9,37 ຕື້
9,77 ຕື້
10,00 ຕື້
9,40 ຕື້
Operating income
5,46 ຕື້
4,58 ຕື້
3,86 ຕື້
4,12 ຕື້
Other non operating income
-13,00 ລ້ານ
-7,00 ລ້ານ
-130,00 ລ້ານ
4,00 ລ້ານ
EBT including unusual items
4,53 ຕື້
4,20 ຕື້
3,22 ຕື້
3,84 ຕື້
EBT excluding unusual items
5,16 ຕື້
4,29 ຕື້
3,49 ຕື້
3,78 ຕື້
Income tax expense
507,00 ລ້ານ
266,00 ລ້ານ
814,00 ລ້ານ
683,00 ລ້ານ
Effective tax rate
11,19%
6,34%
25,30%
17,79%
Other operating expenses
-4,00 ລ້ານ
70,00 ລ້ານ
190,00 ລ້ານ
42,00 ລ້ານ
Net income
4,04 ຕື້
3,93 ຕື້
2,41 ຕື້
3,16 ຕື້
Net profit margin
27,24%
27,36%
17,38%
23,34%
Earnings per share
2,42
2,25
2,03
1,99
Interest and investment income
-
-
373,00 ລ້ານ
-
Interest expense
-289,00 ລ້ານ
-281,00 ລ້ານ
-304,00 ລ້ານ
-343,00 ລ້ານ
Net interest expenses
-289,00 ລ້ານ
-281,00 ລ້ານ
69,00 ລ້ານ
-343,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
6,56 ຕື້
5,78 ຕື້
4,96 ຕື້
5,24 ຕື້
Gain or loss from assets sale
-67,00 ລ້ານ
81,00 ລ້ານ
80,00 ລ້ານ
-159,00 ລ້ານ
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more